Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SPIOMET phase II trial in adolescent girls and young adult women with PCOS
2021-003177-58Phase 2Active
- Sponsor
- Fundació Sant Joan de Déu
- Start
- Dec 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of spironolactone, pioglitazone and metformin in polycystic ovary syndrome (PCOS) (2 arms), sponsored by Fundació Sant Joan de Déu. Primary endpoint: On-treatment and post-treatment ovulation rate. Started Dec 2021; status: active.
02
Drugs
spironolactonepioglitazonemetformin
03
Conditions
polycystic ovary syndrome (PCOS)
Beyond the preview
Go deeper on 2021-003177-58.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-003177-58.